Management of Metoprolol Succinate in Patients with Pulmonary Concerns

Introduction to Metoprolol Succinate and Pulmonary Function

• Metoprolol succinate can adversely affect pulmonary function in patients with reactive airway disease, though its beta-1 selectivity makes it less likely to cause bronchospasm compared to non-selective beta blockers 1, 2
• The American College of Cardiology (ACC) and American Heart Association (AHA) guidelines caution about using beta blockers, including metoprolol, in patients with reactive airways disease 1, 2

Guidelines for Beta Blocker Use in Pulmonary Disease

• The ACC/AHA guidelines list "reactive airways disease" as a contraindication to beta blocker therapy in the management of ST-elevation myocardial infarction 2
• The ACC/AHA/HRS guidelines note that beta blockers are typically avoided in patients with severe underlying pulmonary disease, particularly those with bronchospasm 1, 3
• The American College of Cardiology recommends that metoprolol can be used in multifocal atrial tachycardia (MAT) after correction of hypoxia or other signs of acute decompensation 3

Risk Stratification and Monitoring

• The American Heart Association suggests risk stratification for patients with pulmonary concerns, including high risk for patients with active bronchospasm, severe COPD, or asthma, moderate risk for stable COPD without recent exacerbations, and low risk for no history of reactive airway disease 1
• The American College of Cardiology recommends baseline pulmonary function testing before initiation, monitoring for symptoms of bronchospasm or worsening dyspnea, and considering regular spirometry in high-risk patients 1

Alternative Approaches

• The American College of Cardiology suggests using the lowest effective dose of metoprolol succinate, ensuring concurrent bronchodilator therapy is optimized, and considering cardioselective alternatives like bisoprolol for patients requiring beta blockade with significant pulmonary disease 3
• The American Heart Association notes that cardioselectivity is dose-dependent, and at higher doses, metoprolol may lose its beta-1 selectivity and affect pulmonary function more significantly 1, 2